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Abstract
Background: Growing amount of scientific evidence suggests that microbes are involved in the pathophysiology
of irritable bowel syndrome (IBS). The predominant fecal microbiota composition of IBS subjects has been widely
studied with DNA-based techniques but less research has been focused on the intestinal pathogens in this
disorder. Here, we optimized a highly sensitive panel of 12 quantitative real-time PCR (qPCR) assays to shed light
on the putative presence of intestinal pathogens in IBS sufferers. The panel was used to screen fecal samples from
96 IBS subjects and 23 healthy controls.
Results: Fifteen IBS samples (17%) tested positive for Staphylococcus aureus with a thermonuclease (nuc) gene-
targeting qPCR assay, whereas none of the healthy controls were positive for S. aureus (p< 0.05). The S. aureus
-positive IBS samples were confirmed by sequencing of the PCR amplicons. Clostridium perfringens was detected
from IBS and control groups with a similar frequency (13% and 17%, respectively) with a-toxin (plc) gene -targeting
qPCR assay while none of the samples tested positive for the Cl. perfringens enterotoxin-encoding gene (cpe).
Conclusions: The qPCR panel consisting of 12 assays for an extensive set of pathogenic microorganisms provides an
efficient alternative to the conventional detection of gastrointestinal pathogens and could accelerate the initiation of
targeted antibiotic therapy reducing the risk of post-infectious IBS (PI-IBS). S. aureus has not been previously reported
to be associated with the onset of IBS. Although we discovered significant differences in the prevalence of S. aureus
between the study groups, its importance in giving rise to IBS symptoms requires further studies.
Background
Irritable bowel syndrome (IBS) is a common multifactorial
functional intestinal disorder of unknown etiology [1]. It is
considered a major cause of abdominal discomfort and
gut dysfunction worldwide with an estimated prevalence
of 10% to 20% of the adult population, which makes it the
most frequent diagnosis in gastroenterology [1-3].
Although not life-threatening, IBS is a major global health
problem resulting in significant sensation of illness, poor
quality of life, a high rate of work absenteeism and consid-
erable health costs [4,5]. IBS is characterized by a variable
combination of chronic and recurrent symptoms including
abdominal pain or discomfort, irregular bowel movements,
flatulence, and constipation or diarrhea [6]. According to
the stool consistency, IBS subjects can be divided into
three subcategories predominant in diarrhea (IBS-D), con-
stipation (IBS-C) or alternating constipation and diarrhea
i.e. the mixed subtype (IBS-M) [1,4,6].
The mechanisms of pathogenesis behind IBS are only
partly understood and thus cannot be traced to a single
organic factor. Instead, IBS is considered a complex biop-
sychosocial condition in which a multitude of mechan-
isms at the central and peripheral level interact [7]. The
proposed mechanisms contributing to the etiology of IBS
symptoms include visceral hypersensitivity, abnormal
motor function, low-grade mucosal inflammation, food
intolerance, altered gut microbiota as well as psychoso-
cial and genetic factors [8-10]. However, it is often diffi-
cult to differentiate between the causes and effects,
especially for chronic impaired states of health [11].
The role of enteric infections in the pathogenesis of
IBS has been recognized for years and the development
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episode of infectious gastroenteritis has been reported in
several prospective studies [12-18]. Infectious diarrhea
due to Escherichia coli 0157:H7, Salmonella, Shigella or
Campylobacter has been shown to precede the develop-
ment of post-infectious IBS (PI-IBS) [15,19,17,20,21].
However, there have been no reports regarding the
involvement of other potentially pathogenic microorgan-
isms on the etiology of the IBS. Furthermore, in PI-IBS
the acute phase of the gastroenteritis has passed and the
expected level of enteric pathogens could be low and
thus difficult to detect. It is noteworthy that even low
levels of enteric pathogen could imply the plausible cau-
sative agent in PI-IBS and contribute to the prolonged
gastric symptoms. Traditionally clinical diagnostics of
enteric infections have relied on conventional culturing
techniques, which lack the potential for convenient
large-scale diagnostics and the adequate accuracy and
sensitivity necessary for low-level sub-clinical detection.
Molecular techniques have expanded our understand-
ing regarding the microbial ecology of the gastrointest-
inal tract [22]. Quantitative real-time polymerase chain
reaction (qPCR) is a powerful advancement of the con-
ventional end-point PCR, which enables quantification
of the target nucleic acid and reduces significantly the
risk of ‘carry-over’ contamination [23]. Generally, the
technique has exceptional performance characteristics
including a wide dynamic range (up to 7 orders of mag-
nitude) and high sensitivity. Therefore, it is a superior
method for the accurate and targeted quantification of
specific bacterial species or groups within microbial
populations. The successful employment of qPCR with
16S rRNA gene -targeted primers for evaluating com-
mensal intestinal bacterial species, groups or genera
from fecal samples of IBS subjects has been reported
previously by our group [24-29]. Here, we investigated
the presence and abundance of selected intestinal
pathogens in fecal samples of IBS subjects and healthy
controls to shed light on the putative role of these bac-
teria in the pathogenesis of IBS. We applied a panel of
12 qPCR assays with SYBR Green I-chemistry targeting
the virulence-associated or 16S rRNA genes and demon-
strated that the qPCR approach has an advantage of
being a highly sensitive and efficient technique for an
extensive quantitative screening of intestinal pathogenic
microorganisms from clinical samples.
Methods
Study subjects
A total of 96 IBS subjects fulfilling the Rome I [30] or II
[6] criteria were recruited by experienced physicians (69
females and 27 males; age 20-73 years; mean 47 years).
The subjects had originally been recruited for two inde-
pendent studies and thus the inclusion and exclusion
criteria were not identical. The IBS group consisted of
subjects with IBS-D or IBS-M (81 subjects) and IBS-C
(15 subjects) (Table 1). Due to two independent sample
sets with different classification criteria, the IBS-D and
IBS-M subgroups were combined for this study. All sub-
jects fulfilling the Rome I criteria (n = 44; 33 females
and 11 males) were 20-73 years of age and their general
condition was confirmed as good by medical experts.
Exclusion criteria for participation included presence of
organic GI diseases, inadequately treated hypertension
or pharmaceutically treated diabetes. Use of statins,
pharmaceutically treated hypertension or coronary
artery disease were not considered exclusion criteria if
medication had been used for at least six months prior
to the study with no changes in dosage. The IBS sub-
jects fulfilling the Rome II criteria (n = 52; 36 females
and 16 males) were 20-65 years of age and had under-
gone clinical investigation and endoscopy or barium
enema of the gastrointestinal tract 0 to 1 years prior to
the study. Exclusion criteria were pregnancy, lactation,
organic intestinal diseases or other severe systematic
diseases, previous major abdominal surgery, severe
endometriosis and dementia. Patients that had received
antimicrobial medication during the previous two
months before the initiation of the study were also
excluded whereas subjects with lactose intolerance were
included if they reported to follow a low-lactose or lac-
tose-free diet. A healthy control group (n = 23; 16
females and 7 males) (Table 1) devoid of gastrointestinal
symptoms was recruited to form a control group for the
IBS subjects. Intestinal disturbances (including lactose
intolerance and celiac disease) and ongoing antibiotic
treatments were considered exclusion criteria for the
control subjects. The fecal samples of the IBS subjects
or healthy controls described above have been analyzed
previously for other microbial species or groups
[24-28,31-33].
The protocol was approved by the Human Ethics
Committee at the Joint Authority for the Hospital
District of Helsinki and Uusimaa (HUS), Finland for
Rome II fulfilling IBS subjects, Kuopio University Hospi-
tal Ethical Committee for research, Finland for Rome I
fulfilling IBS subjects and by the ethical committee of
VTT, Finland for healthy controls. A written informed
Table 1 Characteristics of the IBS subjects and healthy
controls.
IBS-D & IBS-M IBS-C Controls
Number of subjects 81 15 23
Average age (range) 47 (20-73) 49 (24-65) 45 (26-64)
Gender (female/male) 57/24 12/3 16/7
Predominant bowel
habit
Diarrhea or mixed
type
Constipation -
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Participation in the study was voluntary and the subjects
were allowed to withdraw at any point without an
explanation.
Bacterial strains and culture conditions
The pathogenic bacterial strains used as positive and nega-
tive controls in this study included Aeromonas hydrophila
(R5-11-1), Bacillus cereus (ATCC 9139), Campylobacter
jejuni (Neqas 6037), Clostridium difficile (ATCC 9689),
Clostridium perfringens (ATCC 13214), Escherichia coli
EHEC O157:H7 (ATCC 43894), Helicobacter pylori (DSM
4867), Listeria monocytogenes (R14-2-1), Salmonella
enterica serovar Infantis (R5-2-1), Staphylococcus aureus
(ATCC 25923), Yersinia enterocolitica (R5-9-1) and
Yersinia pseudotuberculosis (R5-9-4). E. coli was grown in
Luria broth (Difco, USA) at 37C with shaking (220 r.p.m)
and A. hydrophila, B. cereus, L. monocytogenes, S. Infantis,
S. aureus and Yersinia spp. strains were cultured on blood
agar plates at 37°C. Cl. difficile and Cl. perfringens were
cultured at 37°C in fastidious anaerobe broth (LabM, UK)
supplemented with 1% glucose using anaerobic incubation
(Concept Plus Anaerobe Workstation, Ruskinn Technol-
ogy, UK). C. jejuni and H. pylori were cultivated under
microaerobic conditions at 37°C, using microaerobic
atmosphere-generating system (CampyGen; Oxoid, UK).
C. jejuni was cultured in Campylobacter enrichment broth
(LabM) supplemented with 5% saponin-lysed horse blood
and H. pylori was grown on blood agar plates.
Fecal sample collection and DNA extraction
The fecal samples for bacterial studies were collected
from each study subject and stored in sterile normal
atmosphere containers or anaerobic containers at -80°C
prior to analysis. The chromosomal DNA was isolated
from fecal samples of the study participants as well as
from individual bacterial reference strains. For fecal
samples, the removal of undigested particles by washing
the samples with repeated low-speed centrifugation, col-
lection of the bacteria in the pooled supernatants with
high-speed centrifugation and extraction of chromoso-
mal DNA were performed essentially as described by
Apajalahti et al. [34]. The DNA extraction of the indivi-
dual pure culture reference strains was carried by apply-
ing the bead beating cell disruption technique. Briefly,
the overnight cultured bacterial cells were pelleted by
centrifugation in the presence of glass beads (Ø = 0.1
mm, Edmund Bühler, Germany). Subsequently, the cells
were disrupted by 60 s cell mill homogenization (Bühler
Vibrogen Cell Mill VL4, Edmund Bühler, Germany) and
genomic DNA was purified from the homogenates by
phenol-chlorophorm extraction and ethanol precipita-
tion. Finally, the DNA concentrations of both fecal
DNA preparations and pure culture bacterial genomic
DNA were determined by a fluorometric method based
on the bis-benzimide fluorochrome Hoechst 33258
(Bio-Rad, USA), which fluorescence when bound to
double-stranded DNA. The measurements were per-
formed with a Versafluor fluorometer (Bio-Rad, USA)
with an excitation wavelength of 360 nm and emission
wavelength of 460 nm.
Real-time PCR assays and conditions
The optimized qPCR assay conditions and their oligonu-
cleotide sequences applied in this study are summarized
in Table 2. Briefly, the Salmonella spp. and Aeromonas
spp. assays were set to amplify bacterial targets from the
mentioned genera. The Bacillus cereus group assay
included B. cereus, B. thuringiensis, B. anthracis, B.
mycoides, B. pseudomycoides, B. weihenstephanensis,
which share a high degree of chromosomal sequence
similarity within the 16S rRNA gene. The E. coli assay
targeted both enterohemorrhagic (EHEC) and entero-
pathogenic (EPEC) strains. The remaining assays were
designed to be species-specific. The specificity of the
primer pairs have been validated in earlier publications
(see references listed in Table 2). The oligonucleotide
primers were synthesized commercially by MWG-
Biotech AG, Germany.
The qPCR analyses were performed with the iCycler iQ
Real-Time PCR Detection System (Bio-Rad, USA) using
iCycler IQ 96-well optical grade PCR plates (Bio-Rad,
USA) covered with optical-quality sealing film (Bio-Rad,
USA). The optimal annealing temperatures and MgCl2
concentrations (2.0 mM, 3.0 mM, 4.0 mM or 5.0 mM)
were determined for each assay. The amplification reac-
tions were carried out in triplicate in a volume of 25 μl
with 1:75 000 dilution of SYBR Green I (Molecular
Probes, USA), 10 mM Tris-HCl (pH 8.8), 150 mM KCl,
0.1% Triton X-100, 2-5 mM MgCl2,1 0 0μMe a c hd N T P ,
0.5 μM each primer, 0.6 U Dynazyme II polymerase
(Finnzymes, Finland) and either 5 μl of template, negative
control comprising an extensive set of representative gas-
trointestinal bacterial species or deionized sterile water as
no-template control (NTC). The amplification involved
one cycle at 95°C for 5 min for initial denaturation
followed by 40 cycles of denaturation at 95°C for 15 s,
primer annealing at 50-70°C for 20 s, extension at 72°C
for 30 s and an additional incubation step at 80-85°C for
30 s to collect the fluorescent data. All clinical DNA sam-
ples of IBS subjects and healthy controls were analyzed in
randomized order on several qPCR plates.
Tenfold dilution series of 0.1 pg to 10 ng (correspond-
ing approximately to 30 - 100 to 3.0 × 10
6 -1 . 0×1 0
7
genomic equivalents) of target species genomic DNA
were used as standards in conjunction with 25 ng and
250 ng of each fecal DNA preparation in the same
qPCR run. The following genome sizes for the standard
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for B. cereus group,1 . 6M bf o rC. jejuni, 4.0 Mb for Cl.
difficile,3 . 2M bf o rCl. perfringens,5 . 4M bf o rE H E C
and EPEC, 1.7 Mb for H. pylori, 2.9 Mb for L. monocyto-
genes,4 . 8M bf o rSalmonella spp., 3.5 Mb for S. aureus
and 4.8 Mb for Y. enterocolitica.
To determine specificity of the PCR reactions, a melt
curve analysis was carried out in conjunction with each
amplification runs by slow cooling from 95°C to 60°C,
with fluorescence collection at 0.3°C intervals and a
hold of 10 s at each decrement. For the verification of
correct product size, the PCR amplicons were stained
with ethidium bromide and subjected to electrophoresis
on 2% agarose gels.
Sequencing of Staphylococcus aureus PCR products
In addition to qPCR targeting S. aureus,s e q u e n c i n go f
the PCR amplicons (approximately 279 bp) was carried
out to verify the identity of the obtained gene fragments.
The PCR products were purified with the QIAquick Gel
Extraction Kit (Qiagen, Germany) after excising the
DNA fragments from a 1.25% SeaPlaque agarose gel
(Cambrex, USA), and eluted in 35 μl of elution buffer.
The concentration of the purified amplicons was esti-
mated with serially diluted samples on 0.8% agarose gels
with ethidium bromide staining. The sequencing was
carried out with an ABI 310 Genetic Analyzer (Applied
Biosystems, USA) using the Big Dye Terminator
chemistry (Applied Biosystems, USA). Two sequencing
reactions were performed from individual PCR products
with the S. aureus nuc gene-specific forward and reverse
primers i.e. each amplicon was sequenced on both
strands. Finally, the sequences were processed with
Sequencher™ 3.0 sequence analysis software (Gene
Codes Corporation, USA) and matched to existing Gen-
Bank sequences by using the nucleotide-nucleotide Basic
Local Alignment Search Tool (BLAST) analysis tool of
NCBI National Center for Biotechnology Information
(NCBI) [35].
Data analysis
In qPCR analyses, the numbers of target microbes
remained below the detection limit of respective assays
in the majority of samples. These values may not be
truly zero or missing values, but are caused by technical
limitations of the qPCR technique. Therefore, for data
analysis, the undetected samples were given a value,
which corresponded to the limit of detection of the
respective qPCR assay. The raw bacterial qPCR data
were transformed to log10 ratios of the number of target
genomes in one gram of feces.
For statistical comparison, Pearson’s chi square test
was performed to obtain correlations between the pre-
sence/absence results of pathogen detection by qPCR
and the different subject groups with Stata 9.2 Data
Analysis and Statistical Software. The p-value of the
Table 2 Real-time PCR assays of the pathogen panel applied in this study.
PCR assay
(Target gene)
Sequence (5’-> 3’) Amplicon size
(bp)
Ta
(°C)
MgCl2
(mM)
Reference
Aeromonas spp.
(aerA)
F: GAGAAGGTGACCACCAAGAACA
R: AACTGACATCGGCCTTGAACTC
232 61 2 [57]
Bacillus cereus group
(16S rRNA)
F: TCGAAATTGAAAGGCGGC
R: GGTGCCAGCTTATTCAAC
288 64 3 [58]
Campylobacter jejuni
(hipO)
F: GACTTCGTGCAGATATGGATGCTT
R: GCTATAACTATCCGAAGAAGCCATCA
344 58 3 [59]
Clostridium difficile
(16S rRNA)
F: TTGAGCGATTTACTTCGGTAAAGA
R: CCATCCTGTACTGGCTCACCT
157 58 3 [55]
Clostridium perfringens
(plc)
F: AAGTTACCTTTGCTGCATAATCCC
R: ATAGATACTCCATATCATCCTGCT
283 61 4 [60]
Clostridium perfringens
(cpe)
F: GGTTCATTAATTGAAACTGGTG
R: AACGCCAATCATATAAATTACAGC
154 58 3 [61]
EHEC/EPEC
(eaeA)
F: ATGCTTAGTGCTGGTTTAGG
R: GCCTTCATCATTTCGCTTTC
248 65 4 [62]
Helicobacter pylori
(16S rRNA)
F: GAAGATAATGACGGTATCTAAC
R: ATTTCACACCTGACTGACTAT
139 58 4 [55]
Listeria monocytogenes
(iap)
F: CTAAAGCGGGAATCTCCCTT
R: CCATTGTCTTGCGCGTTAAT
174 61 4 [63]
Salmonella spp.
(invA)
F: GTGAAATTATCGCCACGTTCGGGCAA
R: TCATCGCACCGTCAAAGGAACC
281 64 2 [64]
Staphylococcus aureus
(nuc)
F: GCGATTGATGGTGATACGGTT
R: AGCCAAGCCTTGACGAACTAAAGC
279 60 3 [65]
Yersinia enterocolitica
(ail)
F: GGTCATGGTGATGTTGATTACTATTCA
R: CGGCCCCCAGTAATCCATAA
90 58 4 [66]
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considered statistically significant. In addition, the R
software environment for statistical computing and gra-
phics [36] was applied with R-scripts for data
illustration.
Results
Optimization of the SYBR Green I-based real-time PCR
assays
Quantitative real-time PCR procedures, which utilized
12 previously designed oligonucleotide primer pairs for
the detection of an extensive set of intestinal pathogens,
were optimized for the application in our qPCR quanti-
fication system with SYBR Green I-chemistry. The ratio-
nale for the re-optimization was the fact that majority of
the assays were originally developed for conventional
end-point PCR applications. The primer sequences, tar-
gets organisms, PCR product sizes as well as optimal
annealing temperatures and MgCl2 concentrations are
summarized and listed in Table 2. Although the specifi-
city of the primer pairs has been previously verified, the
potential cross-reactivity of the oligonucleotides was
evaluated using BLAST search of GenBank [35]. For the
16S rRNA-gene-targeted assays, the specificity was
verified also by submitting the primer sequences to
Probe Match program provided by the Ribosomal Data-
base Project (RDP II) [37]. In the in silico analyses, no
cross-reaction with closely related or undesired bacterial
species was observed with any of the primer pairs tested.
A dynamic range of five logs from 0.1 - 1 pg to 10 ng
of specific target genome, which corresponds to
approximately 30 - 100 to 3.0 × 10
6 - 1.0 × 10
7 genomic
equivalents per qPCR reaction was obtained with seven
out of eight assays when serially diluted chromosomal
DNA was used as template. The exception was B. cereus
group assay with the dynamic range of four logs. The
lowered sensitivity of this assay was due to excessive
formation of primer-dimers, which hampered the ampli-
fication of smallest 0.1 pg standards. The sufficient
upper limit of the standard curve was not determined
and could actually be higher further increasing the
dynamic range of the applied assays. In addition, no sig-
nals above the detection limit were obtained from nega-
tive controls with any of the tested assays.
Real-time PCR analysis of pathogens from fecal DNA
samples
A total of 96 IBS and 23 control fecal specimens were
subjected to qPCR analyses with newly optimized assays
targeting a wide variety of intestinal pathogenic bacteria.
The IBS subjects were divided according to their
symptoms into constipation-predominant IBS and diar-
rhea-predominant or mixed-type IBS subgroups. In the
analyses of Aeromonas spp., B. cereus group, EHEC and
EPEC, L. monocytogenes, Salmonella spp. and Y. enteroco-
litica all samples from IBS and control subjects remained
below the limit of detection (~10
4 bacterial genomic
equivalents per gram of sample) of the respective qPCR
analyses. Therefore, with these bacterial species the
qPCR assays could only be tested with the reference
strains. Conversely, in the analysis of S. aureus, Cl.
perfringens, H. pylori and Campylobacter spp. positive
signals were obtained.
The qPCR analysis of S. aureus revealed that 15 IBS
samples (prevalence of 17%) amplified within the linear
range of the standard curve giving a positive result with
the quantities ranging from 2.5 × 10
4 to 4.0 × 10
7 geno-
mic equivalents per gram of feces (Figure 1A). The posi-
tive signals were initially verified by melting curve
analysis (Tm = 83.5°C) and agarose gel electrophoresis.
On the contrary, no positive S. aureus signals were
obtained with the samples from healthy controls. This
result was statistically significant at the risk level of p <
0.05 (Pearson’s Chi-square test). The S. aureus-positive
IBS samples were relatively evenly distributed among
the two subcategories as the frequencies of positive sam-
ples in IBS-D&M and IBS-C subgroups were 16% and
13%, respectively. No clear relation to age or gender was
observed among the S. aureus positive samples.
Figure 1 Real-time PCR results of the assays for Staphylococcus
aureus nuc gene (A) and Clostridium perfringens plc gene (B).
The values are target genomes per gram of fecal sample (log10
values). The detection limit is set to 10
4 bacterial genomes. The
abbreviations: IBS-C and IBS-D&M stand for constipation-
predominant irritable bowel syndrome and diarrhea-predominant or
mixed-type irritable bowel syndrome, respectively.
Rinttilä et al. Gut Pathogens 2011, 3:6
http://www.gutpathogens.com/content/3/1/6
Page 5 of 9In a screening process of fecal specimens with a qPCR
assay targeting the a-toxin encoding the plc gene of Cl.
perfringens, 12 samples of IBS subjects were positive
with the quantities ranging from 5.6 × 10
5 to 2.7 × 10
9
genomic equivalents per gram of feces (Figure 1B). The
obtained signals were verified to be true positives by
melting curve analysis (Tm = 83.5°C) and agarose gel
electrophoresis, which both resulted in identical results
with the reference strain. The highest frequency of posi-
tive samples was observed in the IBS-C subgroup with a
prevalence of 20% while in the IBS-D&M subgroup the
prevalence of Cl. perfringens-positive samples was 11%.
The average age of the subjects yielding a Cl. perfringens
positive signal was 50.5, which is slightly higher as com-
pared to the average age of the IBS subjects. It is note-
worthy that three of the Cl. Perfringens -positive
samples from IBS-D&M subgroup were also discovered
to be positive in the analysis of S. aureus.
In addition to 12 IBS subjects, fecal samples of three
males and one female of the healthy control group pos-
sessed the plc gene-positive Cl. perfringens correspond-
ing to the prevalence of 17%. The quantities ranged
from 9.0 × 10
4 to 6.9 × 10
6 genomic equivalents per
gram of fecal sample (Figure 1B). Due to the relatively
equal prevalence of Cl. perfringens in the different sub-
ject groups, no statistically significant differences with
the Pearson’s Chi-square test were observed. In addition
to the a-toxin gene-targeted real-time PCR, all samples
were screened for cpe, which is a gene encoding entero-
toxin (CPE), a causative agent of Cl. perfringens Type A
food poisoning. No indications of the presence of the
cpe gene possessing Cl. perfringens were observed in
either of the IBS subgroups or healthy controls.
T h eo c c u r r e n c eo fH. pylori was detected in the sam-
ples of three IBS subjects with the average age of 57 years
whereas no positive cases were observed among control
subjects. The H. pylori numbers ranged from 8.3 × 10
5 to
1.0 × 10
7 genomic equivalents per gram of fecal speci-
men. C. jejuni was detected only in one subject belonging
to the IBS-D&M subgroup.
Staphylococcus aureus PCR product verification
The samples yielding a S. aureus signal were confirmed
by sequencing the PCR amplicons and by performing a
BLAST database search against the GenBank sequences.
All 15 sequences were found to be 100% identical and
shared complete sequence similarity with the thermonu-
clease precursor (nuc)g e n eo fS. aureus subsp. aureus
in the GenBank database. Hence, based on the obtained
sequencing results in conjunction with the correct
melting curve profile (Tm = 83.5°C) of the amplicons,
the obtained findings were regarded as ‘true positives’ of
S. aureus.
Discussion
A comprehensive investigation of the gut microbiota is
fundamental for the understanding of the role of bac-
teria in IBS. Therefore, predominant enteric bacteria in
the fecal samples of IBS subjects have been widely stu-
died with different DNA-based techniques [24,29,38-40].
To our knowledge, however, there are relatively few
reports focusing on the detection of intestinal patho-
gens, the abundance of which is likely to be significantly
lower as compared to dominant microorganisms present
in the gut. Moreover, as PI-IBS is considered a pro-
longed state of functional gastrointestinal symptom trig-
gered by an acute gastroenteritis, the level of the
original causative agent may be much lower or even
undetectable after the acute phase of an enteric infec-
tion has passed. Thus, much of the data regarding the
role of pathogens as causative agents of IBS is likely to
be limited since the routine clinical investigations com-
monly rely on bacterial culturing techniques possibly
lacking the sufficient sensitivity for detecting low levels
of pathogens from fecal specimens. In this study, our
aim was to discover whether the selected intestinal
pathogenic bacterial species or groups are associated
with IBS in comparison with healthy controls even at
low detectable levels by applying a highly sensitive
qPCR approach with the primer pairs targeted either to
a virulence gene or the 16S rRNA gene.
An extensive qPCR screening of fecal DNA samples
revealed that S. aureus was detected in IBS subjects with
a frequency (17%) that differed from that of the control
group with a statistical significance. S. aureus is a food-
borne pathogen known to cause food poisoning but it is
difficult to obtain accurate estimates of the precise inci-
dence of S. aureus intoxications since many cases are
not specified or reported. The disease occurs as a result
of the ingestion of foods or beverages containing one or
more preformed enterotoxins (SE) produced by the
species and it is characterized by symptoms including
diarrhea, nausea and abdominal cramps [41]. Classically,
SEs have been divided into five major serological types
(SEA, SEB, SEC, SED, and SEE) on the basis of their anti-
genic properties [42] but during the last decade, nine
new types have been discovered (SEG to SEO). In this
study, we targeted the nuc gene as a common S. aureus
marker in the real-time PCR analyses. Therefore, the
occurrence of enterotoxin producing strains within the S.
aureus positive samples detected remains to be evaluated.
It is noteworthy, however, that in a study by Pinto and
coworkers [43], a total of 40 out of 131 food isolates ana-
lyzed were positive for the se genes (prevalence of 31%),
the sec genotype being the most frequent.
Thus far, S. aureus has not been reported to be asso-
ciated with the onset of IBS although there is evidence
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enteritis in approximately 15% of subjects (for review
see Smith and Bayles [44] as well as Spiller and Garsed
[11]). The common bacteria, which have been
associated with PI-IBS include the foodborne pathogens
C. jejuni, E. coli O157:H7 and Salmonella spp.
[13,15,19,45,46]. In this set of fecal samples, one IBS
subject was C. jejuni -positive but no signals of Salmo-
nella or enteropathogenic and enterohaemorrhagic
E. coli were observed. The association between H. pylori
infection and IBS subjects has been reported by Su et
al. [47]. They discovered that 33 of the 69 subjects
included in the study (a prevalence of 47.8%) had
H. pylori infection, which was associated with functional
dyspepsia. In our qPCR analysis, H. pylori was detected
in three IBS subjects one of which harbored H. pylori at
relatively high level (~10
7 genomic equivalents per gram
of feces; data not shown). This IBS subject had been
previously treated for H. pylori but the treatment period
was not fully completed. It is worth mentioning that the
most common habitat of H. pylori is the human sto-
mach and the beginning of the upper digestive tract.
Here, all the analyses were carried out on fecal samples,
which may explain the lack of positive cases. Although
previous gastroenteritis was not an inclusion criterion
for the IBS subjects in this study, the obtained results
in conjunction with earlier findings by other researches
suggests that a number of different gastroenteritis-indu-
cing bacteria may be involved in IBS. Hence, it is indeed
likely that the inflammatory response of the host rather
than a particular individual pathogenic species is prob-
ably the key factor triggering the onset of IBS [48]. It
remains unclear, however, whether the different patho-
genic species pose an equal risk of developing the
disorder.
Cl. perfringens was detected from IBS and control
groups with a similar frequency when targeting the gene
encoding a-toxin (plc). This result along with the fact
that Cl. perfringens is a commensal species in the stool
of some normal healthy subjects [49] implies that there
is no association between Cl. perfringens and the patho-
genesis of the IBS at least within the subjects of this
study. Furthermore, the detection Cl. perfringens entero-
toxin in fecal samples has been suggested to be the defi-
nitive method of implicating this organism as the cause
of diarrhea and abdominal cramps due to the gastroen-
t e r i t i s[ 5 0 ] .I nt h i ss t u d y ,n o n eo ft h es a m p l e st e s t e d
positive for the chromosomally located Cl. perfringens
enterotoxin-encoding gene (cpe).
Complex microbial communities and challenging
sample matrix make DNA extraction from feces tech-
nically demanding. Fecal matter contains several inhi-
bitory factors such as bile salts, haemoglobin
degradation products and complex polysaccharides
that can have significant adverse effects on the effi-
ciency and sensitivity of PCR-based assays [51-53].
Fecal PCR inhibitors generally exert their effects by
interacting with target DNA or blocking the enzyme
activity of thermostable DNA polymerases [54]. Hence,
the best way to avoid PCR inhibition is to prevent the
inhibitor from being processed with the sample.
Another prerequisite for a successful molecular analy-
sis of complex microbiota is the efficiency of cell dis-
ruption step and subsequent recovery of bacterial
DNA. It is apparent that if the isolated DNA does not
accurately represent the microbial composition of the
original sample due to inefficient cell lysis, the results
obtained will be unreliable and biased. The good
recovery rates of fecal bacterial DNA extraction
method applied in this study [34] have been confirmed
earlier by our research group [55]. The feasibility of
the technique was also recently further demonstrated
in a comparative study in which four widely used DNA
extraction protocols were evaluated [56].
In this report, we introduced an optimized and
validated panel of qPCR assays applicable for highly sen-
sitive and specific high-throughput gastrointestinal
pathogen detection from clinical samples. A total of 12
pairs of oligonucleotide primers for several common
pathogenic species or groups were carefully selected
from earlier publications. The specificity of these
primers was reconfirmed by applying both in silico and
in vitro analyses and the optimal qPCR conditions were
determined. As a result, with this pathogen panel the
target bacteria were detectable at a minimum concentra-
tion range of approximately 10
4 bacterial genomes per
gram of fecal sample, which corresponds to the sensitiv-
ity to detect 0.000001% subpopulations of the total fecal
microbiota.
Conclusions
We applied the newly optimized panel for the screening
of an extensive set of fecal DNA samples of IBS subjects
in order to shed light on the putative role of pathogenic
bacteria in IBS. Although significant differences in the
prevalence of S. aureus between the study groups were
observed, its importance in giving rise to IBS symptoms
requires further studies. Nevertheless, the results
obtained indeed support the earlier suggestions with
regards to the role of intestinal pathogens in IBS.
Overall, the qPCR panel optimized and validated in
this study provides a feasible and efficient alternative to
the conventional detection of gastrointestinal pathogens
and thus could accelerate the initiation of targeted anti-
biotic therapy reducing the risk of PI-IBS. However, the
future challenge will be to fine-tune the analysis pipeline
from the sample preparation to real-time PCR in order
t oo b t a i nt h er e s u l t sw i t h i ni n3t o4h o u r s .T h i sw o u l d
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laboratories, the diagnostics of which rely currently on
the bacterial culturing techniques.
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